SEC Form 4	
------------	--

 $\square$ 

## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	ROVAL
OMB Number:	3235-028

L	I	
l	hours per response:	0.5
l	Estimated average burden	

1. Name and Address of Reporting Person <sup>*</sup> BOGER JOSHUA S			2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]		ationship of Reporting Person(s) to Issuer ( all applicable) Director 10% Owner		
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS			3. Date of Earliest Transaction (Month/Day/Year) 02/03/2016		Officer (give title below)	Other (specify below)	
50 NORTHERN (Street)	AVENUE		4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	lividual or Joint/Group Filing (Check Applicable		
BOSTON	МА	02210			Form filed by More than C Person	0	
(City)	(State)	(Zip)					

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Disposed Of			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)
Common Stock	02/03/2016		М		5,130	A	\$35.35	270,414	D	
Common Stock	02/03/2016		<b>S</b> <sup>(1)</sup>		200	D	\$86.66 <sup>(2)(3)</sup>	270,214	D	
Common Stock	02/03/2016		<b>S</b> <sup>(1)</sup>		500	D	\$88.11(3)(4)	269,714	D	
Common Stock	02/03/2016		<b>S</b> <sup>(1)</sup>		1,100	D	<b>\$89.6</b> <sup>(3)(5)</sup>	268,614	D	
Common Stock	02/03/2016		<b>S</b> <sup>(1)</sup>		1,300	D	<b>\$90.63</b> <sup>(3)(6)</sup>	267,314	D	
Common Stock	02/03/2016		S <sup>(1)</sup>		700	D	<b>\$91.58</b> <sup>(3)(7)</sup>	266,614	D	
Common Stock	02/03/2016		<b>S</b> <sup>(1)</sup>		800	D	<b>\$</b> 92.94 <sup>(3)(8)</sup>	265,814	D	
Common Stock	02/03/2016		<b>S</b> <sup>(1)</sup>		530	D	<b>\$93.61</b> <sup>(3)(9)</sup>	265,284	D	
Common Stock								13,286	I	401k
Common Stock								122,700	I	Common Stock Held In Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	Derivative Security (Instr. 3) Date (Instr. 3) Date (Month/Day/Year) Date (Month/Day/Year) Date (Month/Day/Year) Nice of Code (Instr. (Month/Day/Year) Securities Security (Month/Day/Year) Securities Security (Month/Day/Year) Securities Security (Instr. 3) Securities Security (Instr. 5) Securities Securities Security (Instr. 5) Securities Security (Instr. 5) Securities Sec														
1. Title of Derivative Security (Instr. 3)	Conversion or Exercise Price of	Date	Execution Date, if any	Transa Code (		of Deri Sec Acq (A) Disp of (I	vative urities uired or oosed O) tr. 3, 4	Expiration Date (Month/Day/Year)		Amount of Securities Underlying		Derivative Security (Instr. 5)	derivative Securities Beneficially	Ownership Form: Direct (D)	of Indirect
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$35.35	02/03/2016		М			5,130	(10)	07/19/2016	Common Stock	5,130	\$0.00	112,870	D	

Explanation of Responses:

1. Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.

2. Open market sales reported on this line occurred at a weighted average price of \$86.66 (range \$86.37 to \$86.94).

3. Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

4. Open market sales reported on this line occurred at a weighted average price of \$88.11(range \$87.82 to \$88.30).

5. Open market sales reported on this line occurred at a weighted average price of \$89.60 (range \$89.15 to \$90.08).

6. Open market sales reported on this line occurred at a weighted average price of \$90.63 (range \$90.20 to \$91.07).

7. Open market sales reported on this line occurred at a weighted average price of \$91.58 (range \$91.25 to \$92.22).

8. Open market sales reported on this line occurred at a weighted average price of \$92.94 (range \$92.32 to \$93.15).

9. Open market sales reported on this line occurred at a weighted average price of \$93.61 (range \$93.34 to \$93.96).

10. Fully vested.

1.

Omar White, Attorney-In-Fact 02/05/2016

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $\ast$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.